You'd best add the caveat of them being autlogous cells and not allogeneic, or you will get told off.
But indeed a significant milestone for the FDA as I posted in other threads, in that it is their first approval of genetically engineered CAR T-Cell therapy. - "TECELRA is a melanoma-associated antigen A4 (MAGE-A4)-directed genetically modified autologous T cell immunotherapy indicated for the treatment of adults with unresectable or metastatic synovial sarcoma...." (Adaptimmune)
I think the real relevancy for MSB is the nature of the approval:
"As part of the accelerated approval, a confirmatory trial will be required" (my embolden). It was granted on the back of a 44 patient trial. Another turning of the tide of the FDA approval regime that many have spoken about hopefully with regard to MSB on there threads.
https://www.fiercepharma.com/pharma/adaptimmune-scores-fda-nod-first-engineered-cell-therapy-solid-tumor
Another small positive development in the regulatory backdrop for MSB's FDA ambitions.
- Forums
- ASX - By Stock
- Cell Therapy News/Articles
You'd best add the caveat of them being autlogous cells and not...
-
- There are more pages in this discussion • 181 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add MSB (ASX) to my watchlist
|
|||||
Last
96.0¢ |
Change
0.025(2.67%) |
Mkt cap ! $1.096B |
Open | High | Low | Value | Volume |
95.0¢ | 96.5¢ | 94.0¢ | $1.231M | 1.291M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
4 | 94461 | 95.0¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
96.0¢ | 61151 | 6 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
4 | 94461 | 0.950 |
6 | 59977 | 0.945 |
9 | 154571 | 0.940 |
4 | 44875 | 0.935 |
5 | 92633 | 0.930 |
Price($) | Vol. | No. |
---|---|---|
0.960 | 61151 | 6 |
0.965 | 46785 | 5 |
0.970 | 48228 | 6 |
0.975 | 64461 | 2 |
0.980 | 31269 | 3 |
Last trade - 16.10pm 12/09/2024 (20 minute delay) ? |
Featured News
MSB (ASX) Chart |